Omnicare Clinical Research Opens New Office in South Korea
King of Prussia, PA
Omnicare Clinical Research announced that it has opened an office in Seoul, Korea.
“Since 2006, we have been conducting studies in South Korea with a local partner,” said Benoit Martin, President, International for Omnicare Clinical Research. “Opening our own office in Seoul enables us to strengthen our presence in the Asia Pacific Region, as well as reinforce our global commitment to our clients. The new facility will also create added value in response to the Japanese Authorities’ mandate to provide data outside of Japan.”
Omnicare Clinical Research has had a presence in the Asia Pacific Region since its Australia office opened in 1985. The company has other offices in the area including: Beijing and Shanghai, China; Singapore; Taipei, Taiwan; Tokyo, Japan; and Bangalore, India.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
